New antibody combo takes aim at Hard-to-Treat lymphoma

NCT ID NCT05737628

Ongoing Disease control Sponsor: Byondis B.V. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BYON4228 (a lab-made antibody) combined with rituximab (a cancer drug)
What this could lead to: If it works, this could point toward a new treatment option for people with certain types of lymphoma that haven't responded to other therapies.
What could go wrong: This is a very early (Phase 1) and small trial (17 people), so it's mainly checking safety. The drug may not work well or could have side effects, and it's too soon to know if it will help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

ASST Spedali Civili di Brescia

Brescia, Italy
Centro Integral Oncológico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro

Madrid, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Spain
IRCCS Ospedale San Raffaele

Milan, Italy
Institut Català d'Oncologia

Barcelona, Spain
Instituto Europeo di Oncologia

Milan, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST

Ravenna, Italy
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS

Candiolo, Italy
Radboud UMC

Nijmegen, Netherlands
The Christie NHS Foundation Trust

Manchester, United Kingdom
University Hospitals Plymouth NHS Trust

Plymouth, United Kingdom
Vrije Universiteit Medisch Centrum

Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.